Full Press Release Details
BIONDVAX PHARMACEUTICALS LTD.
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
To Be Held on August 24, 2023
The Annual General Meeting of Shareholders of
BiondVax Pharmaceuticals Ltd. (the "Company") will be held at the offices of Goldfarb Gross Seligman & Co., One
Azrieli Center, Tel Aviv, Israel on August 24, 2023, at 4:00 p.m. Israel time, or at any adjournments thereof (the "Meeting")
for the following purposes:
| 4. | To approve an amendment to the Company's Articles of Association to provide that the Company is required to appoint external directors under the Israel Companies Law, 5759-1999 ("Companies Law") only to the extent required by the Companies Law and the regulations thereunder. | |
| 5. | To approve amendments to the annual cash compensation paid to our independent directors. |
In addition, shareholders at the Meeting will
have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended December 31,
The Company is currently unaware of any other
matters that may be raised at the Meeting. Should any other matters be properly raised at the Meeting, the persons designated as proxies
shall vote according to their own judgment on those matters.
Only holders of record of ordinary shares, no
par value (the "Ordinary Shares"), and holders of record of ADSs, evidenced by American Depositary Receipts issued
by The Bank of New York Mellon, at the close of business on July 10, 2023 (the "Record Date"), shall be entitled to
receive notice of and to vote at the Meeting.
The Board of Directors recommends that you vote
"FOR" each of the proposals, as specified in the form of proxy to be provided separately.
Whether or not you plan to attend the
Meeting, it is important that your Ordinary Shares or ADSs be represented. Accordingly, you are kindly requested to (i) vote online
or (ii) complete, date, sign and mail the proxy to be provided separately at your earliest convenience. Execution of a proxy
will not in any way affect a shareholder's right to attend the Meeting and vote in person, and any person giving a proxy has
the right to revoke it at any time before it is exercised.
ADS holders should return their proxies by the
date set forth on their form of proxy.
This Notice and the documents mentioned therein,
as well as the proposed resolutions on the agenda, can be viewed at the Company's registered office on Jerusalem BioPark, 2nd
Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, Tel: +972-(8)-930-2529, Sunday through Thursday between 10:00-15:00, and also will
be made available to the public on the Company's website http://www.biondvax.com, and the SEC's website at http://www.sec.gov.
| By Order of the Board of Directors, | |
| Mark Germain | |
| Chairman of the Board of Directors |